PROGRAM DESCRIPTION

Although considerable improvements have been made in the short-term outcomes of kidney transplantation, long-term patient and graft outcomes have not improved to the same degree. In addition to patient deaths, viral infection is a major factor limiting efforts to optimize outcomes. Cytomegalovirus (CMV), a pathogen encountered frequently in solid organ transplant recipients, impacts transplantation outcomes through both direct and indirect effects. In 2009, the first comprehensive guidelines were published addressing measures to improve long-term outcomes of kidney transplantation, including immunosuppressive protocols and infection control.

This program will review individualized immunosuppressive protocols (for both induction and maintenance), and will discuss infection-control strategies for CMV. The faculty will review the new KDIGO guidelines and their use in the care of kidney transplant recipients. A case study will be presented allowing for interaction with the listeners.

Faculty

	David R. Snydman, MD, FACP (Chair) (read bio) Hospital Epidemiologist & Chief, Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Professor of Medicine Tufts University School of Medicine Boston, MA
	Daniel C. Brennan, MD, FACP (read bio) Professor of Medicine Washington University in St. Louis Director of Transplant Nephrology St. Louis, MO
	Don Hricik, MD (read bio) Professor of Medicine, Case Western Reserve University Chief, Division of Nephrology and Hypertension Medical Director, Transplant Service University Hospitals Case Medical Center Cleveland, OH
	Bertram L. Kasiske, MD (read bio) Professor of Medicine & Director, Renal Division Head, Transplant Nephrology Hennepin County Medical Center University of Minnesota Minneapolis, MN

AGENDA

TARGET AUDIENCE

This program is developed for transplant physicians, transplant surgeons, transplant nephrologists, transplant coordinators, and other members of the transplant team.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

1. Describe the effects of and risk factors for CMV infection and disease among kidney transplant recipients
2. Summarize strategies for preventing and/or minimizing CMV infection and disease among kidney transplant recipients
3. Discuss the new KDIGO guidelines and their application to clinical practice regarding CMV in kidney transplantation

ACCREDITATION

The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE INFORMATION

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME, as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

David R. Snydman, MD, FACP: Speaker: Novartis, Genzyme, Millenium, Viropharma, CSL Behring; Research Grants: AstraZeneca, Johnson & Johnson, Merck; Speaker: Cubist, Merck, CSL Behring

Daniel C. Brennan, MD, FACP: Investigator: Novartis, Genzyme, Pfizer, LCP, Chimerix; Consultant: Novartis, Genzyme, Pfizer; Speaker: Genzyme

Don Hricik, MD: Nothing to Disclose

Bertram L. Kasiske, MD: Research Grant: Genzyme, Bristol-Myers Squibb, Merck/Schering-Plough; Consultant: Litholink

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Otto Ratz, MD; Stef Stendardo, Brad Pine; Blair St. Amand; Jay Katz; Dana Simpler, MD: Nothing to Disclose

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Sponsored by:	Supported by an educational grant from

By clicking this button you are agreeing that you have read and understood the CME Statements above.